Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novartis, and Servier all agreed to share drug discovery data – but not with each other directly, nor with Owkin. Instead ...

Adam, whose name has been changed to protect his identity, has been drinking cups of tea or orange juice secretly laced with drugs since 2021 to enable doctors to administer the AstraZeneca ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics.

(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient ...

Shares of AstraZeneca (NASDAQ:AZN) declined earlier this week after the company and its partner Daiichi Sankyo (OTCPK:DSNKY) presented disappointing overall survival data from the phase 3 trial of ...

The late-stage trial has been closely watched by investors and analysts who forecast that the drug, known as Dato-DXd, could potentially be another best-selling medicine for AstraZeneca.

LONDON, Sept 9 (Reuters) - Detailed results from one of AstraZeneca's (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not ...